Apricus Biosciences to Present at the 2013 Stifel Nicolaus Healthcare Conference

Apricus Biosciences to Present at the 2013 Stifel Nicolaus Healthcare

SAN DIEGO, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), today
announced that Richard Pascoe, Chief Executive Officer, will present at the
2013 Stifel Nicolaus Healthcare Conference, being held at The Four Seasons
Hotel in Boston, MA. Mr. Pascoe's presentation will take place on Wednesday,
September 11, 2013 at 9:10 a.m. Eastern Time.

The presentation will be webcast and accessible to the public online at
http://www.veracast.com/webcasts/stifel/healthcare2013/23103651508.cfm or via
the Company's website at http://www.apricusbio.com. A replay will be available
for 30 days after the presentation.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual
health. The Company has one approved product, Vitaros^®, for the treatment of
erectile dysfunction, which is now approved in Europe and Canada and will be
commercialized by Apricus Bio's marketing partners, which include Abbott
Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG
(Sandoz), and Bracco SpA. Femprox^®, the Company's product candidate for the
treatment of female sexual interest/arousal disorder, has successfully
completed a nearly 400-subject proof-of-concept study.

For further information on Apricus Bio, visit http://www.apricusbio.com.

CONTACT: Apricus Bio Investor Relations:
         David Pitts or Lourdes Catala
         Argot Partners

Apricus logo
Press spacebar to pause and continue. Press esc to stop.